Prosecution Insights
Last updated: November 20, 2026
Application No. 18/436,088

TREATMENT OF FIBROSIS

Non-Final OA §112
Filed
Feb 08, 2024
Priority
Dec 16, 2015 — GB 1522186.4 +4 more
Examiner
MERTZ, PREMA MARIA
Art Unit
1674
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
National University of Singapore
OA Round
1 (Non-Final)
72%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
556 granted / 774 resolved
+11.8% vs TC avg
Strong +35% interview lift
Without
With
+34.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
42 currently pending
Career history
798
Total Applications
across all art units

Statute-Specific Performance

§101
6.8%
-33.2% vs TC avg
§103
23.7%
-16.3% vs TC avg
§102
13.0%
-27.0% vs TC avg
§112
45.9%
+5.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 774 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election of Group I (claims 21-39; species: A. organ system: respiratory system; B. organ: lung; C. Fibrotic disease: pulmonary fibrosis) in the reply filed on 9/24/2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claims 29, and 38 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions. Claims 1-20 have been canceled. Claims 21-28, 30-37, and 39 are under consideration by the Examiner. Information Disclosure Statement 3. The information disclosure statements (IDS) submitted on 9/24/2026, 7/15/2024, and 2/8/2024 are in compliance with the provisions of 37 CFR 1.97 and have been considered by the examiner. Applicant is reminded of their duty to disclose to the Office all information known to the person to be material to patentability as defined in 37 CFR 1.56. As stated therein, “[e]ach individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section”. Claim Rejections - 35 USC § 112(a)– written description 4. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. 4a. Claims 21-28, 30-37, and 39 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claims contain subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventors, at the time the application was filed, had possession of the claimed invention. This is a written description rejection. The claims require administering a human or humanized monoclonal anti-human Interleukin 11 (IL-11) antibody which inhibits IL-11 mediated signaling; wherein an antibody that inhibits IL-11 mediated signaling is an antibody which inhibits transforming growth factor beta 1 (TGFβ1)-mediated activation of human fibroblasts to alpha smooth muscle actin (αSMA)-positive fibroblasts. The specification does not describe which administered antibody is responsible for the functions claimed (See Example 14, pages 82-85). Rather, the specification states that these potential antibodies must first be screened in an assay to ascertain if the antibodies have the functions required by the instant claims. Although the specification provides a few examples of potential generic agents, it fails to disclose the structures common to all members of the genus of antibodies encompassed by the broad definition provided by Applicant (See specification, page 22, lines 13-33). The specification does not disclose the structure of all of the claimed variant agents that are administered in the claimed method of treatment and fails to disclose which regions of the antibodies are responsible for the functions claimed. In the absence of a known or disclosed correlation between structure and function, claims which encompass variants defined by their function are generally not considered described. Applicant is directed to MPEP § 2163 for guidelines on compliance with the written description requirement. Here, Applicant has not described a reasonable number of members of the genus of antibodies that inhibit IL-11 from binding to its receptor, i.e. the required starting materials for the claims, but rather has presented the public with an idea of how to perform an assay that might identify some agents that fall within the scope of the claim. Of course, depending on what agents are used in the screening assay, it may well identify none. The Court of Appeals for the Federal Circuit addressed claims of this sort in great detail in University of Rochester v. G.D. Searle and Co. (69 USPQ 2nd 1886, CAFC 2004). In Rochester, the Federal Circuit upheld the district court's ruling that patent claims which recited administration of compounds not disclosed, but rather to be identified in a screening assay, were invalid on their face. The specification provides examples of antibodies that binds to IL-11 as broadly claimed (See page 22, lines 13-33). The specification does not describe the structure of the full genus of antibodies responsible for the functions claimed. The Federal Circuit has clarified Written Description as it applies to antibodies in the recent decision Amgen v. Sanofi, 872 F.3d 1367 (Fed. Cir. 2017). The Federal Circuit explained in Amgen that when an antibody is claimed, 35 U.S.C. 112(a) (or pre-AIA first paragraph) requires adequate written description of the antibody itself. Amgen, 872 F.3d at 1378-79. The Amgen court expressly stated that the so-called “newly characterized antigen” test, which had been based on an example in USPTO-issued training materials and was noted in dicta in several earlier Federal Circuit decisions, should not be used in determining whether there is adequate written description under 35 U.S.C. 112(a) for a claim drawn to an antibody. Citing its decision in Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., the court also stressed that the “newly characterized antigen” test could not stand because it contradicted the quid pro quo of the patent system whereby one must describe an invention in order to obtain a patent. Amgen, 872 F.3d at 1378-79, quoting Ariad, 598 F.3d 1336, 1345 (Fed. Cir. 2010). In view of the Amgen decision, adequate written description of an antigen alone is not considered adequate written description of a claimed antibody to that antigen, even when preparation of such an antibody is routine and conventional. Id. While generically the structure of antibodies is known, the structure of the presently recited antibodies can vary substantially within the above given claimed recitations. As noted in Amgen, knowledge that an antibody binds to a particular epitope on an antigen tells one nothing at all about the structure of the antibody, wherein “instead of analogizing the antibody-antigen relationship to a ‘key in a lock,’ it [is] more apt to analogize it to a lock and ‘a ring with a million keys on it.” (Internal citations omitted). The relevant antibody art confirms this quandary, indicating that “knowledge of an epitope or antigen used to generate a monoclonal antibody is insufficient for making the original antibody available, even if suitable in vitro test systems for screening are used.” (See page 8, lines 3-5 of WO 2009/033743 A1). Therefore, those of skill in the art would not accept that the inventor had been in possession of the full genus of antibodies in the present claims. Functionally defined genus claims can be inherently vulnerable to invalidity challenge for lack of written description support, especially in technology fields that are highly unpredictable, where it is difficult to establish a correlation between structure and function for the whole genus or to predict what would be covered by the functionally claimed genus. Abbvie Deutschland GMBH & Co. v. Janssen Biotech, Inc. (759 F.3d 1285 (Fed. Cir. 2014). “When a patent claims a genus using functional language to define a desired result, the specification must demonstrate that the applicant has made a generic invention that achieves the claimed result and do so by showing that the applicant has invented species sufficient to support a claim to the functionally-defined genus." Capon v. Eshhar, 418 F.3d 1349 (Fed. Cir. 2005). Here, the administered antibody is claimed only by function, i.e. binding to IL-11 and inhibiting IL-11 mediated signaling. Consequently, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus of antibodies nor guidance as to which of the myriad of molecules encompassed by the claimed antibodies would meet the limitations of the claims. Further, given the well-known high level of polymorphism of immunoglobulins and antibodies, the skilled artisan would not have recognized that Applicant was in possession of the vast repertoire of antibodies encompassed by the claimed invention. Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111 (Fed. Cir. 1991), clearly states that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the ‘written description’ inquiry, whatever is now claimed.” (See page 1117). The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See Vas-Cath at page 1116). The skilled artisan cannot envision the detailed chemical structure of the genus of claimed agents to be used in the instant method, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of identification. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The compound itself is required. See Fiers v. Revel, 25 USPQ2d 1601 at 1606 (CAFC 1993) and Amgen Inc. v. Chugai Pharmaceutical Co. Ltd., 18 USPQ2d 1016 (Fed. Cir. 1991). Therefore, the instant claims do not meet the written description provision of 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph. Claim Rejections - 35 USC § 112(b) 5. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 5a. Claims 21-28, 30-37, and 39 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 21 is rejected as vague and indefinite for several reasons. Claim 21, lines 8, 12, is vague and indefinite because it recites “human fibroblasts” and it is unclear if these fibroblasts are from the human subject to be treated or from a specific sample of control fibroblasts. Furthermore, claim 21, lines 10-19, recites the limitation “first sample of human fibroblasts”, “second sample of human fibroblasts”, “first culture” and “second culture” it is unclear if these fibroblasts are from the human subject to be treated or from a specific sample of control fibroblasts. Claim 21, lines 14-15, is vague and indefinite because it recites “determining the proportion of αSMA-positive fibroblasts in the first and second culture” and it is unclear how this proportion is determined. Claim 21, line 16, is vague and indefinite because it recites “lesser proportion” which is a relative term and it is unclear how much “lesser” the proportion of αSMA-positive fibroblasts in the first culture is to the proportion of αSMA-positive fibroblasts in the second culture. Claim 21, lines 5-6, is improper because it recites non-elected subject matter. It is required that the claim be amended to delete the recitation of non-elected subject matter in response to this action. Claim 22, lines 2-7, is vague and indefinite because it recites the term “about”. For example, the recitation of “about 3 nanograms/ml and about 7 ng/ml” can encompass “1 ng/ml or even 12 ng/ml”. It is suggested that the term “about” be deleted from the claim to obviate this rejection. Claim 22, line 6, is unclear because it recites “and/or” because it is unclear if both the first and second culture are incubated. It is suggested that the term “and/or” be deleted from the claim to obviate this rejection. Similarly, claim 23, lines 2, 4-5, is vague and indefinite because it recites the term “about”. Similarly, claim 32, lines 2-6, is vague and indefinite because it recites the term “about”. Similarly, claim 33, lines 2-5, is vague and indefinite because it recites the term “about”. Claim 23, line 5, is vague and indefinite because it recites the term “and/or”. It is suggested that the term “and/or” be deleted from the claim to obviate this rejection. Claim 32, line 6, is vague and indefinite because it recites the term “and/or”. It is suggested that the term “and/or” be deleted from the claim to obviate this rejection. Claim 33, line 3, is vague and indefinite because it recites the term “and/or”. It is suggested that the term “and/or” be deleted from the claim to obviate this rejection. Claims 34-35 are vague and indefinite because they recite “and/or”. It is suggested that the term “and/or” be deleted from the claims to obviate this rejection. Claim 24, line 2, is vague and indefinite because it recites “a tissue” and it is unclear which tissue is encompassed by the claim. Claim 25, line 3, is vague and indefinite because it recites the term “and/or”. It is suggested that the term “and/or” be deleted from the claim to obviate this rejection. Claim 26, line 3, is vague and indefinite because it recites the term “and/or”. It is suggested that the term “and/or” be deleted from the claim to obviate this rejection. Similarly, claim 31 is rejected as vague and indefinite for several reasons. Claim 31, lines 4-5, is improper because it recites non-elected subject matter. It is required that the claim be amended to delete the recitation of non-elected subject matter in response to this action. Claim 31, line 7, is vague and indefinite because it recites “human fibroblasts” and it is unclear if these fibroblasts are from the human subject to be treated or from a specific sample of control fibroblasts. Furthermore, claim 31, lines 9, 11, 13, 15-16, recites the limitation “first sample of human fibroblasts”, “second sample of human fibroblasts”, “first culture” and “second culture” it is unclear if these fibroblasts are from the human subject to be treated or from a specific sample of control fibroblasts. Claim 31, lines 13-14, is vague and indefinite because it recites “determining the proportion of αSMA-positive fibroblasts in the first and second culture” and it is unclear how this proportion is determined. Claim 31, line 15, is vague and indefinite because it recites “lesser proportion” which is a relative term and it is unclear how much “lesser” the proportion of αSMA-positive fibroblasts in the first culture is to the proportion of αSMA-positive fibroblasts in the second culture. Claims 27-28, 30, 36-37, and 39 are rejected as vague and indefinite insofar as they depend on claims 21 and 31 for their limitations. Conclusion No claim is allowed. Claims 21-28, 30-37, and 39 are rejected. Advisory Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to PREMA MARIA MERTZ whose telephone number is (571)272-0876. The examiner can normally be reached on Monday to Thursday from 7:30am to 6:00pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, VANESSA FORD, can be reached at telephone number 571-272-0857. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from Patent Center. Status information for published applications may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center for authorized users only. Should you have questions about access to Patent Center, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) Form at https://www.uspto.gov/patents/uspto-automated- interview-request-air-form. /PREMA M MERTZ/ Primary Examiner, Art Unit 1674
Read full office action

Prosecution Timeline

Feb 08, 2024
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799193
ILT7 BINDING MOLECULES AND METHODS OF USING THE SAME
3y 7m to grant Granted Nov 17, 2026
Patent 12799204
METHODS FOR TREATING CANCER USING ANTI-CTLA4 ANTIBODIES
3y 1m to grant Granted Nov 17, 2026
Patent 12799205
COMBINATION THERAPIES FOR TREATING CANCER
3y 1m to grant Granted Nov 17, 2026
Patent 12780918
Antigen Binding Proteins that Bind PD-L1
2y 9m to grant Granted Nov 03, 2026
Patent 12767723
TREATMENT FOR LUPUS NEPHRITIS USING ANTI-BAFFR ANTIBODIES
2y 11m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
72%
Grant Probability
99%
With Interview (+34.6%)
2y 9m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 774 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month